These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 16391401

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
    Barbasso Helmers S, Dastmalchi M, Alexanderson H, Nennesmo I, Esbjörnsson M, Lindvall B, Lundberg IE.
    Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Therapeutic approaches in patients with inflammatory myopathies.
    Dalakas MC.
    Semin Neurol; 2003 Jun; 23(2):199-206. PubMed ID: 12894385
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects.
    Dalakas MC.
    J Neurol; 2006 Sep; 253 Suppl 5():V25-32. PubMed ID: 16998751
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.
    Quick A, Tandan R.
    Curr Rheumatol Rep; 2011 Jun; 13(3):192-8. PubMed ID: 21503696
    [Abstract] [Full Text] [Related]

  • 15. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study.
    Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K.
    Neurology; 1997 Mar; 48(3):712-6. PubMed ID: 9065553
    [Abstract] [Full Text] [Related]

  • 16. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.
    Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E.
    Neurology; 2001 Feb 13; 56(3):323-7. PubMed ID: 11171896
    [Abstract] [Full Text] [Related]

  • 17. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.
    Foreman C, Russo P, Davies N, Hissaria P, Proudman S, Hughes T, Limaye V.
    Intern Med J; 2017 Jan 13; 47(1):112-115. PubMed ID: 28076913
    [Abstract] [Full Text] [Related]

  • 18. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle.
    Zschüntzsch J, Voss J, Creus K, Sehmisch S, Raju R, Dalakas MC, Schmidt J.
    Arthritis Rheum; 2012 Dec 13; 64(12):4094-103. PubMed ID: 22941914
    [Abstract] [Full Text] [Related]

  • 19. [Current therapy for polymyositis and dermatomyositis].
    Chérin P.
    Rev Med Interne; 2008 Jun 13; 29 Spec No 2():9-14. PubMed ID: 18927983
    [Abstract] [Full Text] [Related]

  • 20. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
    Basta M, Dalakas MC.
    J Clin Invest; 1994 Nov 13; 94(5):1729-35. PubMed ID: 7962520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.